Skip to main content
. 2019 Jan 8;157(3):273–282. doi: 10.1530/REP-18-0417

Figure 4.

Figure 4

Role of trophoblast-derived CXCL16 on ESC decidualization in vitro. The in vitro decidualised ESCs were treated with high-glucose DMEM (HG), culture supernatants of trophoblast cells or anti-CXCL16 (5 µg/mL) for 3 days. Decidualised ESCs treated with trophoblast cells supernatants secreted higher IGFBP-1 (A) and PRL (B) in 6 and 9 days (ESCs(cAMP + MPA)+ Tro sup vs ESCs(cAMP + MPA) + HG, **P < 0.01), but the secretion level reduced when added with anti-CXCL16 in 9 days (ESCs(cAMP + MPA)+ Tro sup vs ESCs(cAMP + MPA)+ Tro sup+anti-CXCL16, ★P < 0.05). ESC (cAMP + MPA) + HG, in vitro decidualised ESCs treated with high-glucose DMEM containing 20% v/v FBS; ESC (cAMP + MPA) + Tro sup, in vitro decidualised ESCs treated with supernatants of trophoblast cells; ESC (cAMP + MPA) + Tro sup+anti-CXCL16, in vitro decidualised ESCs treated with supernatants of trophoblast cells and anti-CXCL16; ESC (cAMP + MPA), in vitro decidualised ESCs, ESCs incubated with MPA plus cAMP. Data are expressed as the mean ± s.d. (n = 12). ESCs(cAMP + MPA)+Tro sup vs ESCs(cAMP + MPA)+ HG, **P < 0.01, ***P < 0.001; ESCs(cAMP + MPA) +Tro sup+anti-CXCL16 vs ESCs(cAMP + MPA) + HG, #P < 0.05, ##P < 0.01; ESCs(cAMP + MPA) +Tro sup+anti-CXCL16 vs ESCs(cAMP + MPA) +Tro sup, ★P < 0.05.